{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:53:09Z","timestamp":1783471989207,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rdc.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:10:42Z","timestamp":1749309042000},"page":"495-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Achieving Precision Medicine in Psoriatic Arthritis"],"prefix":"10.1016","volume":"51","author":[{"given":"Shannon","family":"Gunawardana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4 Suppl 98","key":"10.1016\/j.rdc.2025.05.007_bib2","first-page":"9","article-title":"Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity?","volume":"34","author":"McInnes","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.007_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00005792-197409000-00002","article-title":"Associations between ankylosing spondylitis, psoriatic arthritis, Reiter\u2019s disease, the intestinal arthropathies, and Behcet\u2019s syndrome","volume":"53","author":"Moll","year":"1974","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1752-8062.2008.00003.x","article-title":"Right drug-right patient-right time: personalized medicine coalition","volume":"1","author":"Abrahams","year":"2008","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40477-015-0189-7","article-title":"Medical ethics","volume":"19","author":"Valentino","year":"2016","journal-title":"J Ultrasound"},{"key":"10.1016\/j.rdc.2025.05.007_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.007_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.007_bib8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acr.22529","article-title":"Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis","volume":"67","author":"Haddad","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.007_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3899\/jrheum.150805","article-title":"Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-alpha drugs","volume":"43","author":"Perrotta","year":"2016","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.007_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2025.05.007_bib11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2025.05.007_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae006","article-title":"Effectiveness of sequential lines of biologic and targeted small molecule drugs in psoriatic arthritis: a systematic review","author":"Gollins","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.007_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.007_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.007_bib16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10235","key":"10.1016\/j.rdc.2025.05.007_bib18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.007_bib19","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.05.007_bib20","first-page":"S12","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","volume":"20 Suppl 1","author":"Fragoulis","year":"2022","journal-title":"Muscoskel Care"},{"issue":"10","key":"10.1016\/j.rdc.2025.05.007_bib21","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.05.007_bib22","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/annrheumdis-2024-eular.1542","article-title":"AB0433 effectiveness in the axial domain of IL-12\/23 and IL23 inhibitors in axial and\/or mixed psoriatic arthritis: multicenter observational study (APxis-IL12-23)","volume":"83","author":"Almodovar","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1134\/S160767292470087X","article-title":"Evaluation of the possibility of axial psoriatic arthritis patients meeting classification criteria for axial spondyloarthritis and ankylosing spondylitis","volume":"517","author":"Gubar","year":"2024","journal-title":"Dokl Biochem Biophys"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib25","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.007_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.05.007_bib27","article-title":"Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: one year follow-up outcomes","volume":"9","author":"Miyagawa","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.007_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078539","volume":"13","author":"Ooms","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-022-02771-4","article-title":"Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study","volume":"24","author":"Miyagawa","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"10136","key":"10.1016\/j.rdc.2025.05.007_bib30","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.007_bib31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.20090246","article-title":"IL-9 as a mediator of Th17-driven inflammatory disease","volume":"206","author":"Nowak","year":"2009","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","article-title":"Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab","volume":"72","author":"Wagner","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.007_bib33","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/jdv.15431","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Ovejero-Benito","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.007_bib34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.05.007_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2024-eular.4868","article-title":"OP0161 multi-modal analysis of synovial tissue inflammation informs on treatment response in active psoriatic arthritis","volume":"83","author":"Bruno","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.007_bib36","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.jaci.2018.11.042","article-title":"Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab","volume":"143","author":"Visvanathan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.007_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mpmed.2018.01.003","article-title":"Psoriatic arthritis and seronegative spondyloarthropathies","volume":"46","author":"Jadon","year":"2018","journal-title":"Medicine"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2025.05.007_bib38","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1136\/ard.2004.033654","article-title":"Seronegative spondyloarthropathies: to lump or split?","volume":"64 Suppl 2","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.007_bib40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/bjd\/ljad347","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update","volume":"190","author":"Smith","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"22","key":"10.1016\/j.rdc.2025.05.007_bib44","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMms1604593","article-title":"Assessing the gold standard--lessons from the history of RCTs","volume":"374","author":"Bothwell","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdw413","article-title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples","volume":"28","author":"Renfro","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-cancerbio-061421-012927","article-title":"Basket trials: past, present, and future","volume":"8","author":"Murciano-Goroff","year":"2024","journal-title":"Annu Rev Cancer Biol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.007_bib47","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O'Dwyer","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.007_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41575-023-00805-z","article-title":"Innovations to improve the efficiency of phase II IBD clinical trials","volume":"20","author":"Noor","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.rdc.2025.05.007_bib49","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rdc.2025.05.007_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis","author":"Lembke","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"10.1016\/j.rdc.2025.05.007_bib51","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.007_bib52","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2024.04.020","article-title":"Basket, umbrella, and platform trials: the potential for master protocol-based trials in inflammatory bowel disease","volume":"167","author":"Honap","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.007_bib53","first-page":"185","article-title":"Response-adaptive randomization in clinical trials: from myths to practical considerations","volume":"38","author":"Robertson","year":"2023","journal-title":"Stat Sci"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib54","first-page":"77","article-title":"Critical care management of the patient with pulmonary hypertension","volume":"11","author":"Barnett","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"13","key":"10.1016\/j.rdc.2025.05.007_bib55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.rdc.2025.05.007_bib56","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with covid-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"10373","key":"10.1016\/j.rdc.2025.05.007_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib58","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12916-019-1391-9","article-title":"When to keep it simple - adaptive designs are not always useful","volume":"17","author":"Wason","year":"2019","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.007_bib59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.rdc.2025.05.007_bib60","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241240913","volume":"16","author":"Watson","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13063-021-05142-7","article-title":"Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design","volume":"22","author":"Rombach","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.rdc.2025.05.007_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2147","article-title":"The PRECIS-2 tool: designing trials that are fit for purpose","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.007_bib63","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13063-025-08777-y","article-title":"Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial","volume":"26","author":"Ogdie","year":"2025","journal-title":"Trials"},{"issue":"20","key":"10.1016\/j.rdc.2025.05.007_bib65","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMc1504317","article-title":"The cost of drug development","volume":"372","author":"DiMasi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41540-020-00165-3","article-title":"Integrative computational approach identifies drug targets in CD4(+) T-cell-mediated immune disorders","volume":"7","author":"Puniya","year":"2021","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.rdc.2025.05.007_bib67","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2019.00353","article-title":"Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis","volume":"10","author":"Chemin","year":"2019","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2025.05.007_bib68","doi-asserted-by":"crossref","first-page":"ii26","DOI":"10.1136\/ard.2004.031740","article-title":"Immunopathology of psoriasis and psoriatic arthritis","volume":"64 Suppl 2","author":"Veale","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"10.1016\/j.rdc.2025.05.007_bib69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.24242","article-title":"Measuring outcomes in psoriatic arthritis","volume":"72 Suppl 10","author":"Ogdie","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib70","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2025.05.007_bib71","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3899\/jrheum.160904","article-title":"Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016","volume":"44","author":"Orbai","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.05.007_bib72","first-page":"39","article-title":"Composite measures for clinical trials in psoriatic arthritis: testing pain and fatigue modifications in a UK multicenter study","volume":"97","author":"Tillett","year":"2021","journal-title":"J Rheumatol Suppl"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.007_bib73","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10067-023-06605-9","article-title":"Difficult to treat psoriatic arthritis - how should we manage?","volume":"42","author":"Kumthekar","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.007_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.007_bib75","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.007_bib76","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jama.2022.24324","article-title":"Sequential, multiple assignment, randomized trial designs","volume":"329","author":"Kidwell","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2025.05.007_bib77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cct.2017.04.001","article-title":"Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART","volume":"57","author":"Kelleher","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.rdc.2025.05.007_bib78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cct.2017.07.002","article-title":"Program for lung cancer screening and tobacco cessation: study protocol of a sequential, multiple assignment, randomized trial","volume":"60","author":"Fu","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.007_bib79","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"Hojgaard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.007_bib80","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ced.12504","article-title":"Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis","volume":"40","author":"Graceffa","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.007_bib81","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00296-014-2955-9","article-title":"Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity","volume":"34","author":"Salaffi","year":"2014","journal-title":"Rheumatol Int"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.007_bib82","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3899\/jrheum.151491","article-title":"The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study","volume":"43","author":"Brikman","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.05.007_bib83","article-title":"Advances and trends in omics technology development","volume":"9","author":"Dai","year":"2022","journal-title":"Front Med (Lausanne)"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:15:26Z","timestamp":1752711326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889857X25000304"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.007","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving Precision Medicine in Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}